Key result
De-escalating DAPT to a single potent agent at 1-3 months lowers bleeding in Korean PCI patients.
Why the study?
Korean patients have distinct bleeding tendencies, lower ischemic risks, and clopidogrel resistance, creating a need for specific guidelines on optimal antiplatelet therapy after PCI.
What is the optimal duration and de-escalation strategy for antiplatelet and anticoagulation therapy in Korean patients undergoing PCI?
What is the optimal duration and de-escalation strategy for antiplatelet and anticoagulation therapy in Korean patients undergoing PCI?
This review highlights that tailoring DAPT duration and de-escalation strategies based on individual ischemic and bleeding risks is crucial for Korean patients undergoing PCI.
Answers are grounded in this paper and cite their sources.
Supports risk-based DAPT tailoring in Korean PCI patients; leaves open optimal strategies pending dedicated trials.
Dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention (PCI) has been established as the standard therapy.In Korean patients, low response of clopidogrel due to genetic variants was reported, and generally speaking, Korean have been believed to have more bleeding tendency and relatively fewer ischemia with antiplatelet therapy.New potent P2Y12 inhibitors, such as prasugrel and ticagrelor, have been introduced.More bleeding issues in new agents have raised concerns.Thus, the need for more specific guidelines of optimal antiplatelet agents in Korean patients has been aroused.There were many randomized clinical trials evaluating the timing of de-escalation and switching to proper antiplatelet agents.Regarding recent Korean studies, for patients who were stable for 1 to 3 months after PCI, de-escalation of DAPT to a single new potent antiplatelet agent can be considered to lower bleeding risk.In low ischemic risk and elderly patients, the shorter duration of antiplatelet agents can be optimal in preventing major bleeding events.However, in patients with multi-vessel disease or diabetes mellitus, the longer antiplatelet agents will be appropriate.In patients undergoing PCI with concomitant atrial fibrillation (AF), the current guideline recommends triple therapy within 1 month after intervention and deescalation to dual therapy with the anticoagulant agent and P2Y12 inhibitor.We will review the current evidences of DAPT and triple antiplatelet/anti-coagulant therapy in those with PCI with or without AF with the focus on Korean data.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) conducted a review in Percutaneous coronary intervention. De-escalation and short-duration dual antiplatelet therapy vs. Standard duration dual antiplatelet therapy was evaluated. In Korean patients undergoing percutaneous coronary intervention, de-escalation of dual antiplatelet therapy to a single potent agent after 1 to 3 months can be considered to lower bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: